Cowen and Company reiterated their market perform rating on shares of Sanofi (NYSE:SNY) in a research report released on Tuesday, August 1st. Cowen and Company currently has a $52.00 price objective on the stock, up from their previous price objective of $46.00.
SNY has been the topic of several other research reports. HSBC Holdings plc cut shares of Sanofi from a hold rating to a reduce rating in a research report on Friday, April 7th. Zacks Investment Research lowered shares of Sanofi from a buy rating to a hold rating in a research note on Tuesday, April 25th. BidaskClub upgraded shares of Sanofi from a hold rating to a buy rating in a research note on Friday, June 23rd. J P Morgan Chase & Co restated a neutral rating on shares of Sanofi in a research note on Thursday, April 20th. Finally, Argus initiated coverage on shares of Sanofi in a research note on Thursday, April 6th. They set a buy rating and a $50.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $54.00.
Sanofi (NYSE SNY) opened at 48.19 on Tuesday. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The firm’s 50-day moving average is $47.84 and its 200 day moving average is $46.41. The company has a market cap of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88.
Institutional investors have recently made changes to their positions in the stock. Harbour Capital Advisors LLC bought a new position in shares of Sanofi during the first quarter valued at approximately $113,000. Parallel Advisors LLC raised its position in shares of Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after buying an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in shares of Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after buying an additional 776 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after buying an additional 2,098 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares in the last quarter. Institutional investors own 9.90% of the company’s stock.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.